
News|Articles|April 8, 2022
COVID-19 Updates: US Vaccinations, Booster Doses, & Global Data as of April 8, 2022
Author(s)Sydney Jennings
Data from the CDC on boosters and US vaccination rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Advertisement
How many fully vaccinated Americans have received a booster dose?
According to the Centers for Disease Control and Prevention (CDC) as of today, April 8, 2022, at 4:40 PM, EDT:
45.2% of fully vaccinated persons in the US have received a booster dose of COVID-19 vaccine.
What percentage of people across age groups in the US have been fully vaccinated?
• 65.7% of total US population
• 69.9% of US population aged ≥5 years
• 74.1% of US population aged ≥12 years
• 75.6% of US population aged ≥18 years
• 89.3% of US population aged ≥65 years
How many cases of COVID-19 have been confirmed in the US?
According to the Johns Hopkins COVID-19 interactive map , as of today, April 8, 2022 at 4:20 PM, EDT, there have been:
• 80 348 778 confirmed cases and
• 984 934 deaths
• 984 934 deaths
The 3 states with the highest total confirmed cases are:
1. California: 9 128 761
2. Texas: 6 781 186
3. Florida: 5 885 004
2. Texas: 6 781 186
3. Florida: 5 885 004
Deaths: California has the highest number of deaths due to COVID-19 with 89 340 reported fatalities, followed by Texas with 87 665 and Florida with 73 496.
How many cases of COVID-19 have been confirmed globally?
Globally, there have been 496 909 990 confirmed cases, 6 172 850 deaths, and 11 088 901 035 vaccine doses administered.
Newsletter
Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.
Advertisement
Advertisement
Advertisement
Trending on Patient Care Online
1
Topline Real-World Data Show Fezolinetant Improves VMS, Sleep, and Work Productivity in Women With Confirmed Menopausal VMS
2
Elinzanetant Improves Sleep Through VMS-Independent Mechanisms, According to New Pooled Analysis
3
Pooled Safety Analysis Supports Elinzanetant for Vasomotor Symptoms Through 52 Weeks
4
Four Studies Build Evidence for Elinzanetant as a Safe, Effective Nonhormonal Option for Menopausal Vasomotor Symptoms
5